(Q47389774)

15 January 2018

title

Imaging as a tumor biomarker in oncology drug trials for lung cancer: the FDA perspective (English)

1 reference

15 January 2018

1 reference

N Petrick

1

1 reference

15 January 2018

D G Brown

series ordinal

2

1 reference

15 January 2018

O Suleiman

series ordinal

3

1 reference

15 January 2018

K J Myers

series ordinal

4

1 reference

15 January 2018

language of work or name

English

0 references

publication date

1 October 2008

1 reference

15 January 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

15 January 2018

volume

84

1 reference

15 January 2018

issue

4

1 reference

15 January 2018

page(s)

523-525

1 reference

15 January 2018

The Role of Molecular Imaging in Drug Discovery and Development

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.155

The Biomarkers Consortium: on the critical path of drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.155

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.155

Drug Development and the FDA's Critical Path Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.155

inferred from DOI database lookup

7 January 2021

based on heuristic

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.155

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2008.155

1 reference

15 January 2018

1 reference

15 January 2018